PTGX logo

Protagonist Therapeutics (PTGX) Free Cash Flow

Annual FCF

$182.80 M
+$253.64 M+358.02%

December 31, 2024

Summary

Performance

1-Year Change

+358.02%

3-Year Change

+267.76%

5-Year Change

+530.17%

15-Year Change

+5601.72%

PTGX Free Cash Flow Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

90.03%
PTGX annual free cash flow is higher than 90.03% of companies in Healthcare sector

High & Low

All-time High

$182.80 M
PTGX annual free cash flow is currently at an all-time high

3-Year Low

-$108.97 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
PTGX previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
PTGX next annual earnings announcement has not yet been scheduled

OtherPTGXcash flowmetrics:

Annual CFO

$184.15 M
PTGX annual cash flow from operations is $184.15 million

Annual CFF

$25.85 M
PTGX annual cash flow from financing activities is $25.85 million

Annual CFI

-$299.48 M
PTGX annual cash flow from investing activities is -$299.48 million

Annual CAPEX

$1.35 M
PTGX annual capital expenditures is $1.35 million

Quarterly FCF

-$29.49 M
-$850.00 K-2.97%

December 31, 2024

Summary

Performance

3-Month Change

-2.97%

1-Year Change

-2.97%

3-Year Change

-2.97%

5-Year Change

-2.97%

PTGX Quarterly FCF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

14.77%
PTGX quarterly free cash flow is higher than 14.77% of companies in Healthcare sector

High & Low

All-time High

$268.59 M
PTGX quarterly free cash flow is currently -110.98% below its historical high of $268.59 million

3-Year Low

-$37.94 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
PTGX previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 7, 2025
PTGX next earnings announcement is scheduled for May 7, 2025

OtherPTGXcash flowmetrics:

Quarterly CFO

-$29.18 M
PTGX quarterly cash flow from operations is -$29.18 million

Quarterly CFF

$4.03 M
PTGX quarterly cash flow from financing activities is $4.03 million

Quarterly CFI

-$8.72 M
PTGX quarterly cash flow from investing activities is -$8.72 million

Quarterly CAPEX

$310.00 K
PTGX quarterly capital expenditures is $310.00 thousand

TTM FCF

$182.80 M
-$46.43 M-20.25%

December 31, 2024

Summary

Performance

3-Month Change

-20.25%

1-Year Change

-20.25%

3-Year Change

-20.25%

5-Year Change

-20.25%

PTGX TTM FCF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

90.19%
PTGX TTM free cash flow is higher than 90.19% of companies in Healthcare sector

High & Low

All-time High

$230.85 M
PTGX TTM free cash flow is currently -20.82% below its historical high of $230.85 million

3-Year Low

-$119.49 M

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
PTGX previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

May 7, 2025
PTGX next earnings announcement is scheduled for May 7, 2025

OtherPTGXcash flowmetrics:

TTM CFO

$184.15 M
PTGX TTM cash flow from operations is $184.15 million

TTM CFF

$25.85 M
PTGX TTM cash flow from financing activities is $25.85 million

TTM CFI

-$299.48 M
PTGX TTM cash flow from investing activities is -$299.48 million

TTM CAPEX

$1.35 M
PTGX TTM capital expenditures is $1.35 million

Free Cash Flow Formula

FCF = Cash From Operations − CAPEX

Annual FCF

$182.80 M
PTGX annual free cash flow is $182.80 million

Annual CFO

$184.15 M
PTGX annual cash flow from operations is $184.15 million

Annual CAPEX

$1.35 M
PTGX annual capital expenditures is $1.35 million

PTGX Free Cash Flow Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+358.0%-3.0%-20.3%
3 y3 years+267.8%-3.0%-20.3%
5 y5 years+530.2%-3.0%-20.3%

PTGX Free Cash Flow Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+267.8%-111.0%+22.3%-20.8%+253.0%
5 y5-yearat high+267.8%-111.0%+22.3%-20.8%+253.0%
alltimeall timeat high+267.8%-111.0%+22.3%-20.8%+253.0%

Protagonist Therapeutics Free Cash Flow History

DateAnnualQuarterlyTTM
Dec 2024
$182.80 M(-358.0%)
-$29.49 M(+3.0%)
$182.80 M(-20.3%)
Sep 2024
-
-$28.64 M(-110.7%)
$229.23 M(-0.7%)
Jun 2024
-
$268.59 M(-1070.7%)
$230.85 M(-459.8%)
Mar 2024
-
-$27.67 M(-263.3%)
-$64.16 M(-9.4%)
Dec 2023
-$70.84 M(-35.0%)
$16.94 M(-162.7%)
-$70.84 M(-40.7%)
Sep 2023
-
-$27.02 M(+2.3%)
-$119.49 M(+1.4%)
Jun 2023
-
-$26.41 M(-23.1%)
-$117.84 M(+11.9%)
Mar 2023
-
-$34.36 M(+8.4%)
-$105.35 M(-3.3%)
Dec 2022
-$108.93 M(-0.0%)
-$31.70 M(+25.0%)
-$108.93 M(+4.4%)
Sep 2022
-
-$25.36 M(+82.1%)
-$104.36 M(-3.1%)
Jun 2022
-
-$13.93 M(-63.3%)
-$107.73 M(-8.7%)
Mar 2022
-
-$37.94 M(+39.8%)
-$118.01 M(+8.3%)
Dec 2021
-$108.97 M(+49.4%)
-$27.14 M(-5.6%)
-$108.97 M(+8.1%)
Sep 2021
-
-$28.73 M(+18.7%)
-$100.82 M(+14.0%)
Jun 2021
-
-$24.20 M(-16.3%)
-$88.45 M(+3.0%)
Mar 2021
-
-$28.90 M(+52.1%)
-$85.86 M(+17.7%)
Dec 2020
-$72.95 M(+71.7%)
-$18.99 M(+16.1%)
-$72.95 M(+6.6%)
Sep 2020
-
-$16.36 M(-24.3%)
-$68.47 M(+3.7%)
Jun 2020
-
-$21.61 M(+35.2%)
-$66.05 M(+58.6%)
Mar 2020
-
-$15.99 M(+10.2%)
-$41.65 M(-2.0%)
DateAnnualQuarterlyTTM
Dec 2019
-$42.49 M(-15.7%)
-$14.51 M(+4.1%)
-$42.49 M(+11.3%)
Sep 2019
-
-$13.94 M(-601.7%)
-$38.18 M(+13.4%)
Jun 2019
-
$2.78 M(-116.5%)
-$33.67 M(-35.1%)
Mar 2019
-
-$16.83 M(+65.0%)
-$51.91 M(+2.9%)
Dec 2018
-$50.43 M(-1673.1%)
-$10.20 M(+8.2%)
-$50.43 M(-7.4%)
Sep 2018
-
-$9.42 M(-39.1%)
-$54.44 M(+1109.0%)
Jun 2018
-
-$15.47 M(+0.8%)
-$4.50 M(+159.4%)
Mar 2018
-
-$15.35 M(+8.0%)
-$1.74 M(-154.1%)
Dec 2017
$3.21 M(-110.6%)
-$14.21 M(-135.1%)
$3.21 M(-58.2%)
Sep 2017
-
$40.51 M(-419.0%)
$7.68 M(-119.3%)
Jun 2017
-
-$12.70 M(+22.1%)
-$39.83 M(+13.1%)
Mar 2017
-
-$10.40 M(+6.9%)
-$35.23 M(+16.2%)
Dec 2016
-$30.32 M(+105.1%)
-$9.73 M(+39.1%)
-$30.32 M(+18.7%)
Sep 2016
-
-$7.00 M(-13.6%)
-$25.55 M(+13.9%)
Jun 2016
-
-$8.10 M(+47.6%)
-$22.43 M(+25.8%)
Mar 2016
-
-$5.49 M(+10.7%)
-$17.84 M(+20.6%)
Dec 2015
-$14.78 M(+83.8%)
-$4.96 M(+27.7%)
-$14.78 M(+50.5%)
Sep 2015
-
-$3.88 M(+10.8%)
-$9.82 M(+65.3%)
Jun 2015
-
-$3.50 M(+43.8%)
-$5.94 M(+143.8%)
Mar 2015
-
-$2.44 M
-$2.44 M
Dec 2014
-$8.04 M
-
-

FAQ

  • What is Protagonist Therapeutics annual free cash flow?
  • What is the all time high annual FCF for Protagonist Therapeutics?
  • What is Protagonist Therapeutics annual FCF year-on-year change?
  • What is Protagonist Therapeutics quarterly free cash flow?
  • What is the all time high quarterly FCF for Protagonist Therapeutics?
  • What is Protagonist Therapeutics quarterly FCF year-on-year change?
  • What is Protagonist Therapeutics TTM free cash flow?
  • What is the all time high TTM FCF for Protagonist Therapeutics?
  • What is Protagonist Therapeutics TTM FCF year-on-year change?

What is Protagonist Therapeutics annual free cash flow?

The current annual FCF of PTGX is $182.80 M

What is the all time high annual FCF for Protagonist Therapeutics?

Protagonist Therapeutics all-time high annual free cash flow is $182.80 M

What is Protagonist Therapeutics annual FCF year-on-year change?

Over the past year, PTGX annual free cash flow has changed by +$253.64 M (+358.02%)

What is Protagonist Therapeutics quarterly free cash flow?

The current quarterly FCF of PTGX is -$29.49 M

What is the all time high quarterly FCF for Protagonist Therapeutics?

Protagonist Therapeutics all-time high quarterly free cash flow is $268.59 M

What is Protagonist Therapeutics quarterly FCF year-on-year change?

Over the past year, PTGX quarterly free cash flow has changed by -$850.00 K (-2.97%)

What is Protagonist Therapeutics TTM free cash flow?

The current TTM FCF of PTGX is $182.80 M

What is the all time high TTM FCF for Protagonist Therapeutics?

Protagonist Therapeutics all-time high TTM free cash flow is $230.85 M

What is Protagonist Therapeutics TTM FCF year-on-year change?

Over the past year, PTGX TTM free cash flow has changed by -$46.43 M (-20.25%)